Skip to main content

Table 2 Change in study parameters during the follow-up period

From: Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study

Cohort

Dulaglutide, n = 30

Liraglutide, n = 30

Parameter

Baseline Mean ± SEM

Follow-up Mean ± SEM

Change Mean ± SEM

P

Baseline Mean ± SEM

Follow-up Mean ± SEM

Change Mean ± SEM

P

Body weight (kg)

87.17 ± 2.16

82.97 ± 2.05

−4.20 ± 0.47

< 0.001

89.43 ± 2.60

83.60 ± 2.35

−5.83 ± 0.87

< 0.001

BMI (kg/m2)

32.84 ± 0.77

31.312 ± 0 .68

−1.53 ± 0.21

< 0.001

34.92 ± 0.868

32.650 ± 0.77

−2.27 ± 0.33

< 0.001

SBP (mmHg)

134.30 ± 2.71

130.87 ± 2.49

−3.43 ± 2.97

0.258

137.83 ± 2.503

127.60 ± 2.07

−10.23 ± 2.36

< 0.001

DBP (mmHg)

80.73 ± 1.64

78.43 ± 0.914

− 2.30 ± 1.79

0.208

83.47 ± 1.587

80.67 ± 1.51

− 2.80 ± 1.85

0.141

FPG(mg/dl)

175.53 ± 11.45

133.67 ± 6.90

− 41.87 ± 12.72

0.003

160.13 ± 8.17

115.93 ± 5.69

− 44.20 ± 8.05

< 0.001

HbA1c (%)

8.43 ± 0.21

7.411 ± 0.15

−1.017 ± 0.22

< 0.001

8.49 ± 0.26

6.95 ± 0.21

− 1.547 ± 0.22

< 0.001